Nonalkolik karaciğer yağlanması hastalığında oksidatif stres ve PON1 aktivitesi English

Abstract

Amaç: Yapılan son çalışmalar erken atherosklerozun güvenilir bir belirtisi olan artmış karotis intima-media kalınlığı ile nonalkolik karaciğer yağlanması hastalığı arasında bir ilişki olduğunu ortaya koymuştur. Ancak, karotis arter aterosklerozu ile non-alkolik karaciğer yağlanması hastalığı arasında direk bir ilişki olup olmadığı bilinmemektedir. Bu nedenledir ki, bizler lipid hidroperoksit ile serum paraoksanaz ve arilesteraz aktivitelerini PON1 araştırmayı amaç edindik.Materyal ve metod: Çalışmamıza karaciğer biopsileri alınmış 32 hasta ve 28 sağlıklı ve gönüllü kontrol grubu dahil edildi. Serum bazal ve tuz ile uyarılmış paraoksanaz ve arilesteraz aktiviteleri spektrofotometrik olarak ölçülürken, lipid hidroperoksit seviyeleri ise FOX-2 metodu ile çalışıldı.Bulgular: Lipid hidroperoksit seviyeleri control grubu ile karşılaştırıldığında hasta grubunda daha yüksek iken p

Keywords

• PON1 aktivitesi,lipid hidroperoksit,ateroskleroz,nonalkolik karaciğer yağlanması

Serum PON1 activity and oxidative stress in non-alcoholic fatty liver disease

Abstract

Background: Recent studies have shown that non-alcoholic fatty liver disease NAFLD is associated with increased carotid intima-media thickness as a reliable marker of early atherosclerosis, but possible direct relationships between NAFLD and carotid artery atherosclerosis is unknown. Therefore, the aim of this study was to investigate serum paraoxonase and arylesterase activities PON1 along with lipid hydroperoxide LOOH levels.Methods: We studied 32 consecutive patients with biopsy proven NAFLD and 28 healthy controls. Serum basal/saltstimulated paraoxonase and arylesterase activities were detected spectrophotometrically. LOOH levels were measured by the FOX–2 assay. Results: Serum basal/salt-stimulated paraoxonase and arylesterase activities were significantly lower in NAFLD than controls p

Keywords

• PON1 activity,lipid hydroperoxide,atherosclerosis,non-alcoholic fatty liver disease

References

1. )Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–8.
2. )Brunt EM, Janney CG, Di Bisceglie, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
3. )Del Ben M, Baratta F, Polimeni L, Angelico F. N o n - a l c o h o l i c f a t t y l i v e r d i s e a s e a n d cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg Med 2012; 7: 291-6.
4. )Brea A, Mosquera D, Martin E, et al. Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: Case–Control Study. Arterioscler Thromb Vasc Biol 2005; 25: 1045–50.
5. )Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003; : 977–86.
6. )Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119–21.
7. )Volzke H, Robinson DM, Kleine V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol ; 11: 1848–53.
8. )Colak Y, Karabay CY, Tuncer I, et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012; 24: 613

9. )Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance a n d e n d o t h e l i a l d y s f u n c t i o n i n normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005; 35: 369–74.
10. )Sheth SG, Gordon FD, Chopra S. Non alcoholic steatohepatitis. Ann Intern Med 1997; 126: 137–45.
11. )Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–28.
12. )Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allergy Immunol 2009; 37: 4-11.
13. )Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: –904.
14. )Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low-density lipoprotein. J Clin Invest 1995; 96: 2882–91.
15. )Canales A, Sanchez-Muniz FJ. Paraoxanase something more than an enzyme? Med Clin (Barc) ; 121: 537–48. )Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.Atherosclerosis 1993; 104: 129-35.
16. )Mackness MI, Abbott C, Arrol S, et al. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829–34.
17. )Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330–5.
18. )Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolemia a n d i n s u l i n - d e p e n d e n t d i a b e t e s m e l l i t u s . Atherosclerosis 1991; 86: 193–6.
19. )Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812–8.
20. )Sutherland WH, de Jong SA, Walker RJ. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant 2004; 19: 75–82.
21. )Pasqualini L, Cortese C, Marchesi S, et al. Paraoxonase 1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183: 349-54.
22. )O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90: 18–21.
23. )Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima–media thickness in nonalcoholic fatty liver disease. Am J Med 2008; : 72–8.
24. ) Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 2007; : 776–80.
25. )Baskol M, Baskol G, Deniz K, Ozbakır O, Yucesoy M. A new marker for lipid peroxidation: Serum paraoxonase activity in non-alcoholic steatohepatitis. Turk J Gastroenterol 2005; 16: 119
26. )Ş. Selek, R. Alp, S.İ. Alp, A. Taşkın. Relationship between PON1 phenotype and headache duration in migraine patients. Turk J Med Sci 2011; 41: 177
27. )Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4- nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem 1992; 30: 391–5.
28. )Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999; : 58-62.
29. )Ludwig J, McGill DB, Lindor KD. Nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12: 403.
30. )Goto T, Onuma T, Takebe K, et al. The influence of fatty liver on insulin resistance in non-diabetic Japanese subjects. Int J Obes 1995; 19: 841–5.
31. )Ikai E, Ishizaki M, Suzuki Y, et al. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995; 9: 101–5.
32. )Horoz M, Bolukbas C, Bolukbas FF, et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol ; 5: 35. )Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000; 23: 57-63.
33. )Targher G, Bertolini L, Padovani R, et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004; 27: 2498-500.
34. )Targher G, Bertolini L, Rodella S, et al. NASH p r e d i c t s p l a s m a i n f l a m m a t o r y b i o m a r k e r s independently of visceral fat in men. Obesity 2008; 16: –9.
35. )Krus S, Turjman MW, Fiejka E. Comparative morphology of the hepatic and coronary artery walls. Part I. Differences in the distribution and intensity of non-atherosclerotic intimal thickening and atherosclerosis. Med Sci Monit 2000; 6: 19–23.
36. )Baskol G, Demir H, Baskol M, et al. Assessment of paraoxonase 1 activityand malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 2005; : 951–5.
37. )Baskol G, Baskol M, Yurci A, et al. Serum paraoxonase 1 activity and malondialdehyde levels in patients with ulcerative colitis. Cell Biochem Funct ; 24: 283–6. )Ferre N, Camps J, Cabre M, et al. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001; 9: 997–1000.